BA TTE CANCER CENTER - Atrium Health...multidisciplinary approach improve outcomes and patient satisfaction. Holistic programs and services support cancer patients and their families

2 0 1 0 A N N U A L R E P O R T( U S I N G 2 0 0 9 S T A T I S T I C A L D A T A )

BA

TT

E

CA

NC

ER

C

EN

TE

R

Carolinas Medical CenterNorthEast

Batte Cancer Center

2011NE CancerAnnualReportv6_2010Figures 7/31/12 5:51 PM Page 2

1

Cancer Committee Chairman’s Report . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2

Cancer Liaison Physician’s Report . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3

Nurse Navigators Navigators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4

CyberKnife Stereotactic Radiosurgery at

CMC-NorthEast . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5

Breast Care at CMC-NorthEast . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8

Cancer Data Services Statistics

Review of Analytic Accessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .10

Leading Sites of New Cases and Deaths – 2010 Estimates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .12

Age Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .13

Race Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .13

TNM Stage Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .14

Stage by Sex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .14

State and National Comparison . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .15

County Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16

Contact Us . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .17


2

As a highly respected regional referral center, Batte Cancer Center at CarolinasMedical Center-NorthEast delivers state-of-the art care - from high leveldiagnostics to advanced therapeutics. For patients with complex clinicalconditions, our excellent medical and surgical programs include critical care,infectious disease, pulmonary medicine, surgical and gynecologic oncology andradiology. As an affiliate of Levine Cancer Institute, Batte Cancer Center, alongwith Blumenthal Cancer Center at Carolinas Medical Center, serves as one oftwo tertiary referral centers for cancer care within the network.

In 2010, Batte Cancer Center continued to improve its oncology servicesprogram and to monitor progress through our Cancer Committee. Notableachievements included:

• Clinical: Expanded capabilities with radioactive microsphere therapy through interventionalradiology, offering more treatment options for patients with metastatic and primary liver tumors.

• Community Outreach: Monitored the availability and utilization of screening colonoscopy andmammography in our community and ways to increase education.

• Quality: Monitored compliance with NCCN guidelines within our institution, finding a high degreeof compliance.

• Programmatic: Expanded clinical navigator program capabilities with the addition of a thoracicnavigator. We were also an integral part of the establishment of Levine Cancer Institute.

Our 2011 goals include:

• Clinical: Expansion of therapeutic tools with implementation of endobronchial ultrasoundcapabilities. We also are continuing efforts to standardize molecular diagnostic testing to providecost-effective, state-of-the-art care.

• Community Outreach: Expansion of education programs related to cancer awareness and screening.

• Quality: Monitoring of compliance with NCCN guidelines and improved communication andnavigation pathways among the services involved in the care of cancer patients.

• Programmatic: Integration into Levine Cancer Institute, moving toward system-wide accreditationby the American College of Surgeons (ACoS) and an expanded clinical trials program.

These are exciting times for CMC-NorthEast’s Batte Cancer Center, and for cancer care in general. Therange and complexity of healthcare options for cancer patients poses a challenge for us as we strive toprovide exceptional care in a well-integrated and cost-effective manner. Our cancer program isoutstanding, with continued high confidence and satisfaction expressed by our patients. This is, nodoubt, due to the hard work and dedication of the physicians, nurses and staff who provide care at alllevels. We are excited about our future as a part of Levine Cancer Institute in changing the course ofcancer care for patients throughout the Carolinas and beyond.

Respectfully submitted,

Richard F. Williams MD, PhD, FACPChairman, Cancer CommitteeCarolinas Medical Center-NorthEast

Cancer Committee Chairman’s Report

RICHARD F. WILLIAMS, MD,PHD, FACP


The cancer liaison physician at CMC-NorthEast’s Batte Cancer Center serves in a leadership role for theoncology services program to support our goal of delivering the highest quality of care to patients incompliance with standards set by the Commission on Cancer. A very important component of this goalis community outreach that extends well beyond the medical center campus. Independent andcollaborative efforts, including education, early detection and support for patients and families, arecritical components of our cancer program.

CMC-NorthEast is an innovative leader in cancer care. Here, revolutionary treatments through amultidisciplinary approach improve outcomes and patient satisfaction. Holistic programs and servicessupport cancer patients and their families and serve as models for other facilities.

Our expanded navigator program continues to expedite the evaluation of new patients and ensurecompliance with evidence-based guidelines. A wide range of programs and services are available to cancerpatients and their families, including support groups such as:

• Changing the Face of Cancer

• Caregiver Connections

• Look Good…Feel Better (Breast Cancer)

• Pink Ribbon Friends

• Circle of Hope

• Men for Living

• Flight for Hope

Additionally, we partner with the local chapter of the American Cancer Society to provide cancer supportservices to the community.

NorthEast Foundation is conducting a community campaign to raise 3.2 million dollars to expand theBob and Carolyn Tucker Hospice House. Our program provides physical comfort and emotionalsupport to ensure quality of life for patients, many of whom have battled cancer and reached the limits oftheir endurance. Plans to double the number of patient rooms at Hospice House will greatly expand theservices provided by this invaluable community resource.

On a personal note, it has been a rewarding year of service as cancer liaison physician. Along with othermembers of the Cancer Committee, I look forward to another year in this role with our outstandingcancer program. The cancer care professionals at CMC-NorthEast’s Batte Cancer Center are among thefinest in the country, and it has been a pleasure serving with them in our campaign against cancer.

James North, MD

Cancer Liaison Physician’s Report

3


NAVIGATING THE COURSE OF CANCER CARE

Navigating the complexities of cancer care can be a challenge for patients and caregivers. As the incidenceof cancer continues to increase, meeting the physical and psychosocial needs of patients can be asignificant task. Apart from the psychological aspect of a cancer diagnosis, decisions regarding treatmentoptions, scheduling multiple physician appointments and securing referrals can be overwhelming.Oncology nurses are pivotal to a patient’s successful journey through the cancer experience, even as carehas shifted to an outpatient setting.

Patient navigators can make a real difference in whether someone becomes a cancer survivor. Ifnavigators become involved early in cancer diagnosis, they can steer patients and families to appropriatecare and treatment that could dramatically improve their chances of managing the disease and improvingquality of life.

At Carolinas Medical Center-NorthEast’s Batte Cancer Center, nurse navigators are master’s preparednurses who receive annual education to provide quality patient care and navigation of cancer services.With more than 300 contacts per month, Cindy Wise, MSN, OCN, CBCN, serves as breast nursenavigator at Batte Cancer Center. Ruth Smith, RN, MSN, is nurse navigator and coordinator for Batte’sBreast Health Center. She averages over 250 patients, clinical breast exams, diagnostics, classes andoutreach activities monthly. A lung nurse navigator joined the program in 2011, with future plans to addnavigators for other diseases.

Nurse Navigators

4


Radiation Oncology

5

CYBERKNIFE® STEREOTACTIC RADIOSURGERY

Scott Lankford, MD, Medical Director, Radiation Oncology and Stacey Parrish, RN, BSN, OCN, Cyberknife Coordinator

CyberKnife is a robotic stereotactic radiosurgery system first conceived to treatbrain tumors. It was designed as a more comfortable “frameless” alternative toother stereotactic radiosurgery systems that require attaching a heavy metallichead-frame directly to a patient’s skull for treatment. CyberKnife’s uniquedesign combines a compact state-of-the-art linear accelerator with an advancedindustrial robot capable of highly accurate movements. This enables the deliveryof high doses of therapeutic radiation over short time intervals withoutsacrificing safety - optimizing outcomes for patients, many of whom havelimited treatment options. CyberKnife has quickly proven to be effective intreating a variety of tumors through the body.

The first CyberKnife patient consultation at Carolinas Medical Center-NorthEast’s Batte Cancer Center occurred in March 2007, with the first treatment in June of that sameyear. In the five years since, 549 patients have been evaluated and 371 treated using CyberKnifetechnology. At Batte Cancer Center, the lung, followed by brain lesions, is the most common treatmentsite using CyberKnife. 51 percent of our CyberKnife patients have had a primary lung cancer. In 2010,Carolinas Medical Center-NorthEast made a significant investment in upgrading its CyberKnifesoftware, resulting in improved lung tracking protocols and reduced numbers of patients who requirefiducial placement for treatment.

CyberKnife offers many advantages over standard linear accelerator-based systems, the most significantbeing its ability to accurately target tumors during treatment. The CyberKnife robot can adjust radiationbeam angles by a fraction of a degree to compensate for the smallest motion of the patient or movementof the tumor. For example, lung tumors that move as a patient breathes can significantly limit theeffectiveness of standard radiation therapyequipment. CyberKnife is designed tosynchronize with the patient’s respirations duringtreatment, allowing radiation to be deliveredaccurately during the respiratory cycle. Thus,significantly higher and more effective doses ofradiation can be safely administered. CyberKnifealso has the ability to track a tumor using fixedpoints on the patient’s spine through metallic gold markers, called fiducials.

As cancer therapies have improved greatly overtime, patients with metastatic cancer now live Figure 1: CyberKnife (image courtesy of Accuray)

SCOTT LANKFORD, MDMEDICAL DIRECTOR,

RADIATION ONCOLOGY


longer and more productive lives. CyberKnife hasproven to be a powerful tool in managing patientswith metastatic disease, particularly those withbrain metastases. These patients comprise aboutone-third of Batte Cancer Center’s CyberKnifetreatments. Standard radiation techniques oftenprove less efficacious in controlling brainmetastases because doses are limited and thepotential side effects are more problematic.CyberKnife overcomes these limits by accuratelydelivering a single, large fraction of radiationdirectly to the metastasis, avoiding significant dosesto surrounding normal brain tissue. ForCyberKnife treatment, we utilize a high resolutionbrain MRI scan with contrast and a fine-cut brainCT scan to create a three-dimensional construct ofthe patient’s brain. The fine detail of these scansenables tumors and normal tissues to be preciselyidentified. The CyberKnife treatment planningcomputer can then be used to generate an inversetreatment plan whereby millions of calculationscan be performed and optimized for each patient.At Batte Cancer Center, we also optimizemanagement of complex brain patients byparticipating in the weekly multidisciplinary BrainConference at Carolinas Medical Center.

In 2010, the American Cancer Society reportedlung cancer as “by far the leading cause of cancerdeath among both men and women. More peopledie of lung cancer than of colon, breast andprostate combined. Overall, the chance that a manwill develop lung cancer in his lifetime is aboutone in 13; for a woman, the risk is about one in16. These numbers include both smokers and non-smokers for whom the risk is much higher.” BatteCancer Center decided to evaluate its experiencetreating potentially curable patients diagnosed withmedically inoperable stage I lung cancer and

Radiation Oncology

6

Jan.-July 201160

June 2010118

June 2009140

June 2008156

June-Dec. 200775

Figure 4: shows the most frequent treatment sites usingCyberKnife

OtherProstateBenign

GI

Bone

Brain

Lung

Other 4%

Prostate 3%

Benign 4%

GI 8%

Bone 11%

Bra

in 3

2%

Lung 38%

Primary Brain 1%

Lung M

ass 2%

GYN

2%

Other 2%

H&

N 3%

Prostate 4%

Benign Tumors 4%GU 6%

Melanoma 8%

Breast 8

%

GI

9%

Lung Cancer 51%

Figure 3: shows the diversity of patients treated

Figure 2: shows CyberKnife patient consultations atCMC-NorthEast’s Batte Cancer Center since 2007


Radiation Oncology

7

PR 14%

POD 2%Pending FU 2%

NR 3%

No FU Available 22%

Dec

ease

d Pr

ior

to

CR 54%

FU 3

%

Figure 5: shows our response data for the 63 patients.Many patients come to Batte Cancer Center from faraway. In these instances, follow-up scans may not havebeen available for review and appear as “No FUavailable.”

CR = Complete ResponsePR = Partial ResponseNR = No Response

POD = Progression of DiseaseNo FU Available = Follow-up Outside CMC

NetworkPending FU = Recently Treated Patients Not

Yet Due for Follow-up ScansDeceased Prior to FU = Self Explanatory

Response to Treatment93%

No Response or Disease Progression

7%

representing a large proportion of ourCyberKnife patient population. To date, 63patients with inoperable stage I lung cancer havebeen treated. Of those, seven were PET-positive,un-biopsied lung lesions. The majority ofpatients received three fractions of 18-20 Gy pertreatment for a total dose of 50-64 Gy. PET/CTscan is the most sensitive imaging tool fordiagnosing these patients and measuring theirresponse to CyberKnife treatment. For mostpatients, response was measured with aPET/CT scan done three months afterCyberKnife therapy. FDG activity and tumorsize were the criteria used to determineresponses.

Looking specifically at all patients for whom atleast one follow-up scan was available for review,CMC-NorthEast observed a 93 percentresponse rate (CRs and PRs) using CyberKnifeto treat inoperable stage I lung cancer. Thiscompares favorably to published series andexceeds historical controls.

Carolinas Medical Center-NorthEast’s BatteCancer Center is fortunate to be able to offerCyberKnife Stereotactic Radiosurgery to ourpatients. We have found it to be a safe andeffective tool in treating a wide variety oftumors, both curatively and for palliation.Looking ahead, we will continue to monitorand evaluate our CyberKnife patients andensure that our program remains anindispensable part of the Levine CancerInstitute network.

Figure 6: Overall Response to Treatment


BREAST CARE

Of the 11.7 million cancer survivors in the United States, 2.5 million are breastcancer survivors. In women, breast cancer is the most common cancerdiagnosed and, after lung cancer, the leading cause of cancer death. More than200,000 cases of breast cancer will be diagnosed in the United States this year,claiming more than 40,000 lives.

Thanks to mammography, self-breast and clinical breast exams, breast cancermortality declined between 1992 and 1996. According to a Women’s HealthInitiative reporting a connection between HRT and increased cardiac risk, theincidence of breast cancer decreased by two percent each year from 1999 to2006. Survival at five years for individuals with breast cancer is 85 percent. At

Carolinas Medical Center-NorthEast’s Batte Cancer Center, that number is 82 percent.

While breast health has long been a priority for Carolinas Medical Center-NorthEast, our history ofcaring for women has its roots in our Women’s Center and Mariam Cannon Hayes Family Center. Here,our commitment to excellence is exemplified in our care of patients dealing with breast cancer. As acomprehensive community cancer center, CMC-NorthEast’s Batte Canter Center provides state-of-the-art care and physicians who are board certified in general, breast and oncology surgery, as well as medicaland radiation oncologists. Our highly specialized services include traditional radiation therapy, partialbreast radiation and genetic counseling, along with advanced technologies such as CyberKnife and linearaccelerator.

Established in 2007, the Breast Health Center at Batte Cancer Center offers:

• digital and diagnostic screening mammography

• ultrasound and ultrasound-guided core biopsy

• breast MRI and MRI-guided biopsy

• stereotactic core biopsy

• Mammacare breast self-exam classes through a certified educator

• Mammogram parties

Additionally, our Mobile Mamography & Health Unit has been providing mammograms in thecommunity since 2001. Recent program enhancements include master’s prepared nurse navigators andan outreach coordinator. Navigation services are available for patients diagnosed with breast and lungcancer, with plans to add navigators for other diseases.

While state-of-the-art technology is vital, a 2007 “Cancer Care for the Whole Patient” report from theInstitute of Medicine advised that all cancer care should:

• Ensure the provision of appropriate psychosocial health services

Breast Care at CMC-NorthEast

8

CINDY WISE, RN


• facilitate effective communication

• identify a patient’s psychosocialneeds

• design and implement a plan thatlinks a patient with psychosocialcare

• coordinate biomedical and •engage and support patients inmanaging illness

• include systematic follow up onevaluating and adjusting a plan ofcare

In 2015, the American College ofSurgeons Cancer Program willinstitute new accreditation standardsrelated to the role of the navigator andpsychosocial care. CMC-NorthEast’sBatte Cancer Center has provided psychosocial care by master’s level social workers as well as nursenavigation services for more than a decade. Additionally, we have extended care to support programs thatinclude:

• Breast Cancer Support Group

• Reach to Recovery

• 2 Young (Young Survivor Support Group)

• Changing the Face of Cancer Advanced Cancer Support Group

• Look Good…Feel Better

• Social work services

• Oncology dietitian

• Image services

• Pet therapy

• Massage and acupuncture

As a comprehensive community cancer center, and in accordance with AcoS care guidelines, BatteCancer Center partners with the YMCA to refer patients to survivor programs such as Stepping ForwardWellness. In addition, our survivorship clinic staffed by oncology nurse practitioners providesinformation about nutrition, exercise, follow-up and survivorship care plans.

9

STAGE

PE

RC

EN

TA

GE

0

20

40

60

80

100

CMC-NorthEast CHS Network

Overall43210

NCDB

BREAST CANCER SURVIVAL RATES 2003


10

Cancer Data Services Statistics-NorthEast

SEXCLASS TNM STAGE

Total A N/A Male Female O I II III IV UNK N/A

All sites 1402 1269 133 651 751 117 402 298 187 214 69 115

Oral cavity 21 21 0 13 8 0 4 3 2 12 0 0

Lip 1 1 0 0 1 0 1 0 0 0 0 0

Tongue 9 9 0 7 2 0 2 1 1 5 0 0

Oropharynx 0 0 0 0 0 0 0 0 0 0 0 0

Hypopharynx 0 0 0 0 0 0 0 0 0 0 0 0

Other 11 11 0 6 5 0 1 2 1 7 0 0

Digestive system 223 221 2 114 109 8 48 46 48 62 6 5

Esophagus 12 12 0 10 2 0 3 0 3 6 0 0

Stomach 14 14 0 9 5 1 4 1 4 3 1 0

Colon 94 93 1 45 49 5 23 17 26 20 3 0

Rectum 34 34 0 19 15 1 8 9 9 6 1 0

Anus/anal canal 5 5 0 2 3 1 0 1 2 1 0 0

Liver 14 14 0 9 5 0 5 3 1 2 0 3

Pancreas 30 29 1 14 16 0 3 10 1 15 1 0

Other 20 20 0 6 14 0 2 5 2 9 0 2

Respiratory system 224 217 7 124 100 2 54 34 43 82 8 1

Nasal/sinus 0 0 0 0 0 0 0 0 0 0 0 0

Larynx 12 12 0 9 3 1 5 2 2 1 0 1

Lung/bronchus 211 204 7 114 97 1 48 32 41 81 8 0

Other 1 1 0 1 0 0 1 0 0 0 0 0

Blood & bone marrow 47 44 3 20 27 0 0 0 0 0 0 47

Leukemia 23 21 2 12 11 0 0 0 0 0 0 23

Multiple myeloma 17 16 1 5 12 0 0 0 0 0 0 17

Other 7 7 0 3 4 0 0 0 0 0 0 7

Bone 1 1 0 0 1 0 0 0 0 1 0 0

Connect/soft tissue 3 2 1 1 2 0 1 1 1 0 0 0

Skin 112 31 81 69 43 36 42 9 3 2 19 1

Melanoma 107 29 78 68 39 36 40 9 3 2 17 0

Other 5 2 3 1 4 0 2 0 0 0 2 1

REVIEW OF ANALYTIC ACCESSIONS


SEXCLASS TNM STAGE

11

Total A N/A Male Female O I II III IV UNK N/A

Breast 244 243 1 1 243 40 72 86 25 7 14 0

Female genital 68 67 1 0 68 5 30 6 18 6 3 0

Cervix uteri 9 9 0 0 9 0 2 2 3 1 1 0

Corpus uteri 32 31 1 0 32 0 23 4 2 3 0 0

Ovary 17 17 0 0 17 0 3 0 11 1 2 0

Vulva 7 7 0 0 7 3 2 0 1 1 0 0

Other 3 3 0 0 3 2 0 0 1 0 0 0

Male genital 162 131 31 162 0 0 48 89 12 4 9 0

Prostate 154 123 31 154 0 0 40 89 12 4 9 0

Testis 7 7 0 7 0 0 7 0 0 0 0 0

Other 1 1 0 1 0 0 1 0 0 0 0 0

Urinary system 95 93 2 67 28 26 39 7 6 12 5 0

Bladder 51 50 1 41 10 22 14 6 1 5 3 0

Kidney/renal 38 37 1 22 16 1 24 1 4 6 2 0

Other 6 6 0 4 2 3 1 0 1 1 0 0

Brain & cns 27 26 1 13 14 0 0 0 0 0 1 26

Brain (benign) 4 4 0 3 1 0 0 0 0 0 0 4

Brain (malignant) 13 12 1 6 7 0 0 0 0 0 1 12

Other 10 10 0 4 6 0 0 0 0 0 0 10

Endocrine 87 87 0 24 63 0 46 8 14 5 1 13

Thyroid 74 74 0 17 57 0 46 8 14 5 1 0

Other 13 13 0 7 6 0 0 0 0 0 0 13

Lymphatic system 65 64 1 33 32 0 18 9 15 20 1 2

Hodgkin's disease 6 5 1 4 2 0 0 1 3 1 0 1

Non-hodgkin's 59 59 0 29 30 0 18 8 12 19 1 1

Unknown primary 19 17 2 9 10 0 0 0 0 0 0 19

Other/ill-defined 4 4 0 1 3 0 0 0 0 1 2 1


LEADING SITES OF NEW CASES AND DEATHS – 2010 ESTIMATES

12

Male Female

Prostate Breast217,730 (28%) 207,090 (28%)

Lung & Bronchus Lung & Bronchus116,750 (15%) 105,770 (14%)

Colon & Rectum Colon & Rectum72,090 (9%) 70,480 (10%)

Urinary Bladder Uterine Corpus52,760 (7%) 43,470 (6%)

Melanoma of the Skin Thyroid38,870 (5%) 33,930 (5%)

Non-Hodgkin’s Non-Hodgkin’sLymphoma Lymphoma35,380 (4%) 30,160 (4%)

Kidney & Renal Pelvis Melanoma of the Skin35,370 (4%) 29,260 (4%)

Oral Cavity & Pharynx Kidney & Renal Pelvis25,420 (3%) 22,870 (3%)

Leukemia Ovary24,690 (3%) 21,880 (3%)

Pancreas Pancreas21,370 (3%) 21,770 (3%)

All Sites All Sites739,940 (100%) 739,940 (100%)

Male Female

Lung & Bronchus Lung & Bronchus86,220 (29%) 71,080 (26%)

Prostate Breast32,050 (11%) 39,840 (15%)

Colon & Rectum Colon & Rectum26,580 (9%) 24,790 (9%)

Pancreas Pancreas18,770 (6%) 18,030 (7%)

Liver & Intrahepatic Bile Duct Ovary12,720 (4%) 13,850 (5%)

Leukemia Non-Hodgkin’s 12,660 (4%) Lymphoma

9,500 (4%)

Esophagus Leukemia11,650 (4%) 9,180 (3%)

Non-Hodgkin Lymphoma Uterine Corpus10,710 (4%) 7,950 (3%)

Urinary bladder Liver & 10,410 (3%) Intrahepatic Bile Duct

6,190 (2%)

Kidney & Renal Pelvis Brain & Nervous System8,210 (3%) 5,720 (2%)

All Sites All Sites299,200 (100%) 270,290 (100%)

Estimated New Cases* Estimated Deaths

® 2010, American Cancer Society, Inc. Surveillance and Health Policy Research

* *Excludes basal and squamous cell skin cancers and in situ carcinoma except urinary bladder.


13

Male

Female

AGE RANGE

0

50

100

150

200

250

90 - 9980 - 8970 - 7960 - 6950 - 5940 - 4930 - 3920 - 2910 - 190 - 9

Age Range Male Female

0 - 9 2 2

10 - 19 1 1

20 - 29 3 13

30 - 39 20 45

40 - 49 39 104

50 - 59 124 135

60 - 69 219 207

70 - 79 180 157

80 - 89 55 77

90 - 99 8 10

TOTALS 651 751

Race Cases Percent

White 1,169 83%

Black 135 10%

Other 98 7%

TOTAL 1,402 100%

White

Black

Other

AGE DISTRIBUTION - NORTHEAST

RACE DISTRIBUTION - NORTHEAST


0 I II III IV UNK N/A

0

100

200

300

400

500

TNM STAGE

CA

SES

402

298

117

187214

597

69

115

TNM Stage NBR Cases Percent

0 117 8%

I 402 29%

II 298 21%

III 187 13%

IV 214 15%

UNK 69 5%

N/A 115 8%

TOTAL 1402 100%

STAGE

CA

SES

0

50

100

150

200

250

N/AUNKIVIIIIII0

Male

Female

Stage Male Female

0 49 68

I 173 229

II 144 154

III 79 108

IV 116 98

UNK 36 33

N/A 54 61

TOTALS 651 751

TNM STAGE DISTRIBUTION - NORTHEAST

STAGE BY SEX - NORTHEAST

14


15

STATE AND NATIONAL COMPARISONS - NORTHEAST

0

5

10

15

20

25

30

35

40

Kind of Cancer

PE

RC

EN

TA

GE

CMC Network

NC Estimates

US Estimates

Brea

st

Lung

Pros

tate

Col

orec

tal

Bla

dder

NH

Lym

phom

a

Cor

pus U

teri

Mel

anom

a

Leuk

emia

Cer

vix

All

Oth

er

Type CMC NC US

TOTAL 1402 45,120 15,529,560

percent of total

Breast 17% 14% 14%

Lung 15% 17% 15%

Prostate 11% 15% 14%

Colorectal 9% 9% 9%

Bladder 4% 4% 5%

NH Lymphoma 4% 4% 4%

Uterine 2% 3% 3%

Melanoma 8% 5% 4%

Leukemia 2% 3% 3%

Cervix 1% 1% 8%

All Others 27% 28% 21%


16

NORTH CAROLINA . . . . . . . . . . . . . 1,389

SOUTH CAROLINA . . . . . . . . . . . . . . . . .3

OTHER/OUT OF STATE . . . . . . . . . . . . .10

TOTAL . . . . . . . . . . . . . . . . . . . . . . .1,402

COUNTY DISTRIBUTION OF CANCER CASES - NORTHEAST

1. Alamance 52. Anson 13. Ashe 14. Brunswick 15. Burke 16. Cabarrus 8237. Chesterfield, SC 18. Dillon, SC 1

9. Cumberland 110. Davidson 711. Davie 112. Gaston 213. York, SC 114. Iredell 1615. Lincoln 316. Mecklenburg 62

17. Montgomery 2018. Moore 219. New Hanover 120. Pender 121. Randolph 322. Richmond 123. Rockingham 124. Rowan 220

25. Stanly 20426. Union 627. Wake 228. Watauga 129. Yancey 1

1662

266

51

21

718

81

24220

131

15 3

281

31

2520412

2

6823

1416

41

201

191

107 21

3

221

1720

182

291

91

272

111

15

231


17

For more information on Batte Cancer Center at CMC-NorthEast or to make referrals, please contact us at: 704-403-3369www.cmc-northeast.org

Learn more about our cancer network partners

Blumenthal Cancer Center704-355-2884www.blumenthalcancercenter.org/

CMC-Mercy704-304-5000www.cmc-mercy.org

CMC-Pineville704-667-1000www.cmc-pineville.org

CMC-University704-863-6000www.cmc-university.org

Other ResourcesAmerican Cancer Society800-ACS-2345www.cancer.org

Contact Us


Carolinas Medical CenterNorthEast

Batte Cancer Center


Documents

BA TTE CANCER CENTER - Atrium Health...multidisciplinary approach improve outcomes and patient satisfaction. Holistic programs and services support cancer patients and their families